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Abstract
Background: In the central nervous system regions of the sporadic and familial FTLD and ALS patients, TDP-43 has
been identified as the major component of UBIs inclusions which is abnormally hyperphosphorylated, ubiquitinated,
and cleaved into C-terminal fragments to form detergent-insoluble aggregates. So far, the effective drugs for FTLD and
ALS neurodegenerative diseases are yet to be developed. Autophagy has been demonstrated as the major metabolism
route of the pathological TDP-43 inclusions, hence activation of autophagy is a potential therapeutic strategy for
TDP-43 pathogenesis in FTLD and ALS. Berberine, a traditional herbal medicine, is an inhibitor of mTOR signal
and an activator for autophagy. Berberine has been implicated in several kinds of diseases, including the
neuronal-related pathogenesis, such as Parkinson’s, Huntington’s and Alzheimer’s diseases. However, the therapeutic
effect of berberine on FTLD or ALS pathology has never been investigated.
Results: Here we studied the molecular mechanism of berberine in cell culture model with TDP-43 proteinopathies,
and found that berberine is able to reverse the processing of insoluble TDP-43 aggregates formation through
deregulation of mTOR/p70S6K signal and activation of autophagic degradation pathway. And inhibition of
autophagy by specific autophagosome inhibitor, 3-MA, reverses the effect of berberine on reducing the accumulation
of insoluble TDP-43 and aggregates formation. These results gave us the notion that inhibition of autophagy by 3-MA
reverses the effect of berberine on TDP-43 pathogenesis, and activation of mTOR-regulated autophagy plays
an important role in berberine-mediated therapeutic effect on TDP-43 proteinopathies.
Conclusion: We supported an important notion that the traditional herb berberine is a potential alternative
therapy for TDP-43-related neuropathology. Here we demonstrated that berberine is able to reverse the processing of
insoluble TDP-43 aggregates formation through deregulation of mTOR/p70S6K signal and activation of autophagic
degradation pathway. mTOR-autophagy signals plays an important role in berberine-mediated autophagic clearance of
TDP-43 aggregates. Exploring the detailed mechanism of berberine on TDP-43 proteinopathy provides a better
understanding for the therapeutic development in FTLD and ALS.
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Background
Deposition of the pathological signature proteins in
the brain is the hallmark in various kinds of neurode-
generative diseases. The pathological signature in nu-
merous neurodegenerative diseases are characterized
by the accumulation of intracellular or extracellular
protein aggregates composed of amyloid fibrils [1],
such as senile plaques and neurofibrillary tangle com-
posed of β-amyloid, microtubule associated protein
tau in Alzheimer’s disease (AD), and Lewy bodies
composed of α-synuclein in Parkinson’s disease (PD).
Recently, the 43 kDa nuclear protein TAR DNA-
binding protein (TDP-43) has been identified as a
major component of UBIs aggregated proteins in spor-
adic and familial frontotemporal lobar degeneration
with ubiquitinated inclusions (FTLD-U) as well as
sporadic amyotrophic lateral sclerosis (ALS) [2, 3].
TDP-43 is a 414 amino acid nuclear protein encoded
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by the TARDBP gene on chromosome 1p36.2 and
plays important roles in gene regulation at RNA tran-
scription levels involving in transcriptional repression
and alternative splicing [4, 5]. TDP-43 is highly con-
served in various species including mammals, flies and
caenorhabditis elegans [4, 6] and ubiquitously ex-
presses in all tissues including brain [4, 7]. In about
95 % of ALS and 50 % of FTD cases, the UBI(+)-inclu-
sions are predominately comprised of TDP-43 [8]. The
pathological TAR DNA-binding protein is abnormally
hyperphosphorylated, ubiquitinated, and cleaved into
C-terminal fragments to form cytosolic aggregates in
the central nervous system regions, including hippocam-
pus, frontal cortex, temporal cortex, and spinal cord
motor neuron [2]. Accumulation of TDP-43 within the
Ub-positive insoluble aggregates implies that mis-
regulation of the metabolism of TDP-43, including Ub-
proteasome and autophagy pathways, plays a causative
role in the pathogenesis. Indeed, numerous UPS and
autophagy-related genes are mis-regulated in the frontal
cortex samples of FTLD-TDP patients [9, 10]. Thus, iden-
tification of the potential drugs targeting on modulating
the TDP-43 metabolism pathway might be a potential
therapeutic strategy for FTLD-U and ALS patients with
TDP-43 proteinopathies.
Induction of autophagy is a potential therapeutic tar-
get for accelerating the removal of aggregation-prone
proteins [11]. Most of the misfolded/aggregated proteins
are primarily degraded by autophagy-lysosomal pathway,
which is negatively regulated by the activation of the
kinase mammalian target of rapamycin (mTOR) pathway
[12]. It has been well demonstrated that TDP-43 protein
are degraded through both the ubiquitin-proteasome
[13–15] and autophagy-lysosome metabolism pathways
[16–19]. Nowadays, autophagy metabolism pathway has
been shown to play an important role in TDP-43 deg-
radation and aggregates removal. Depletion of func-
tional multivesicular body (MVBs) required for the
autophagy-lysosome degradation pathway results in the
accumulation of the endogenous TDP-43 in the cytoplasm
as ubiquitinated species [17]. Moreover, autophagy inhib-
ition increases the accumulation of the C-terminal frag-
ments of TDP-43 in cytosol, whereas inhibition of mTOR
by rapamycin reduces the 25-kDa C-terminal fragments
accumulation and restores TDP-43 localization in N2a
and SH-SY5Y cells [16]. Autophagy activation by rapamy-
cin rescues cytosolic TDP-43 mislocalization and trun-
cated TDP-43 neurofilament instability in neurofibroblast
cell lines [16]. The above results suggest that autophagy
induction may be a valid therapeutic target for TDP-43
proteinopathies. The autophagy activator rapamycin is
found to be a potential therapeutic drug in TDP-43-
related pathogenesis [20–22], but its cytotoxicity resulted
in the pathological failures have been observed in ALS
model study [23]. Accordingly, searching for an alternative
drug targeting on activating the autophagy pathway with
less side effect would provide a better therapeutic effect
for TDP-43 pathogenesis in FTLD and ALS.
The traditional herb medicine, berberine, is a potent
autophagy activator through inhibition of the mTOR sig-
nal pathways [24, 25]. Recent studies have demonstrated
that its high tolerance for orally-taken doses and the
freely blood–brain-barrier permeability [26], make it an
ideal alternative drug candidate for numerous neurode-
generative pathogenesis, including Alzheimer’s disease,
Huntington’s disease and Parkinson’s diseases [27–31].
However, the therapeutic effect of berberine on TDP-43-
related neuropathological diseases has never been dis-
cussed. Since berberine is a potent autophagy activator
and activation of autophagy by mTOR inhibition would
result in diminishing the TDP-43 accumulation and res-
cuing in memory/ motor function in rapamycin-treated
cell culture and animal model [16, 22], we assumed that
berberine can ameliorate TDP-43 proteinopathies. Here
we found that berberine could promote the degradation
rates and decrease the aggregates formation of truncated
TDP-43 fragments through activating the autophagic
function in cellular culture model, suggesting that ber-
berine has potential neuroprotective effects on neurode-
generative diseases with TDP-43 proteinopathies.
Methods
Cell culture and DNA transfection
Neuro 2a (N2a) cells were cultured in Eagle’s minimum
essential medium (Invitrogen, Carlsbad, CA, USA), sup-
plemented with 10 % (vol/vol) fetal calf serum and peni-
cillin/streptomycin (Invitrogen). DNA transfection of
N2a cells was carried out with Lipofectamine 2000 (Invi-
trogen) according to the manufacturer’s instructions.
Reagents, recombinant TDP-43 protein, and antibodies
Berberine is a kind gift from Dr. Kuan-Hau Lee. 3-MA
(3-Methyladenine) was purchased from Sigma Aldrich
(Saint Louis, MO, USA). GFP-TDP-25: The cDNA of
human hTDP-43 (NM_007375.3) was cloned into the
HindIII/KpnI restriction sites of pEGFP-C1 vector (Invi-
trogen). For generation of the truncated C-terminal
hTDP-43 fragments (pGFPC1-hTDP-25) (amino acids
175–414), the DNA primers used for PCR amplification
were as follows: forward primer 5’-CGGAAGCTTCG
AATTCTAAGCAAAGCCAA-3’; and reverse primer 5’-
CAGGTACCCTACATTCCCCAGCCAGA-3’. The PCR
product was subcloned into the pEGFP-C1 plasmid
(Invitogen) using restriction sites HindIII and KpnI to
generate pGFP-C1-hTDP-25 (GFP-TDP-25). Antibodies:
Rabbit polyclonal anti-GFP (Invitrogen). Rabbit polyclonal
anti-LC3 (Sigma Aldrich; Cell Signaling, Danvers, MA,
USA). Rabbit polyclonal anti-p-mTOR, anti-mTOR,
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anti-p-p70S6K and anti-p70S6K (Cell Signaling).
Mouse monoclonal anti-α-tubulin (Sigma-Aldrich). Mouse
monoclonal anti-GAPDH (Invitrogen).
Preparation of cell extracts and immunoblotting
Cultured cell were washed twice in PBS and pelleted at
1,000 g for 5 min. To prepare the total cell extracts, the
cell pellets were directly lysed in the urea buffer (Sigma-
Aldrich). For preparation of RIPA-soluble and insoluble
materials [32], the cell pellets were first lysed in the
RIPA buffer (50 mM Tris–HCl, pH 8.0, 150 mM NaCl,
1 % NP-40, 0.5 % sodium deoxycholate, 0.1 % sodium
dodecyl sulfate) freshly supplemented with complete
EDTA-free protease inhibitor cocktail (Roche Applied
Science, Laval, QC, CA) and phosphatase inhibitors
(10 mM NaF and 1 mM Na3VO4) (Sigma-Aldrich). The
protein concentrations of the lysates were determined by
Bio-rad protein assay (Biorad, Marnes-la-Coquette,
France) and then the lysates were centrifuged at 4 °C for
15 min at 12,000 rpm. The supernatants containing the
RIPA soluble material were transferred into new tubes
and boiled in SDS–PAGE sample buffer. The RIPA-
insoluble pellets were washed twice in the lysis buffer,
re-sonicated and re-centrifuged. The washed pellets were
finally dissolved in the urea buffer, sonicated and sup-
plemented with SDS–PAGE sample buffer without
boiling. The soluble proteins and insoluble proteins
were analyzed on SDS–PAGE gels and transferred
onto polyvinylidene difluoride membranes (Immobilon-P,
Millipore). After blocking for 1 h in the blocking buffer
(5 % non-fat dry milk in Tris-buffered saline with 0.1 %
Tween-20), the membranes were stained with the primary
antibodies at 4 °C overnight and then the secondary anti-
bodies at room temperature for 1 h. The bound antibodies
were detected by using the chemiluminescence Western
blotting detection reagent ECL (Amersham Pharmacia
Biotech, Piscataway, NJ, USA).
Immunofluorescence assay and aggregation analysis
N2a cells grown on glass coverslips were transfected
with indicated plasmids. At 48 h post-transfection, the
cells were treated with different inhibitors or drugs for
different periods of time. The cells were fixed with 4 %
ice-cold paraformaldehyde at 4 °C for 20 min and then
permeabilized with PBS–0.5 % Triton X-100 for 7 min
at RT. After blocking with 10 % donkey serum for 1 h at
RT, the cells were incubated overnight at 4 °C with specific
primary antibodies. After washing for three times with
PBS, the cells were incubated at RT for 1.5 h with DAPI
(1:500) (Invitrogen) plus Alexa Fluor 488-conjugated goat
anti-rabbit or Alexa Fluor 488-conjugated goat anti-
mouse IgG secondary antibody (1:500), or plus Alexa
Fluora 546-conjugated goat anti-rabbit or Alexa Fluor
546-conjugated goat anti-mouse IgG secondary antibody
(1:500) (Invitrogen). The images were examined on a
LEICA DM6000B fluorescence microscope and quantified
by MetaMorph software (Molecular Devices, Downing-
town, PA). For quantitative analyses of aggregates, five
representative fields per sample were taken and analyzed
by MetaMorph software. GFP signal was gated to exclude
non-transfected cells, and the images were then superim-
posed with corresponding DAPI images. The Metamorph
was used to count the total number of transfected cells.
For aggregate analyses, the GFP images were visually
adjusted to determine a common threshold across all sam-
ples to eliminate diffuse or non-aggregated signals. The
numbers of individual aggregates were calculated with the
Integrated Morphometry Analysis of Metamorph. The
percentages of aggregated cells were calculated as the fol-
lowing formula: total number of GFP-positive aggregated
cells/total number of transfected cells. Statistical signifi-
cance was analyzed with the student t-test.
Results
The effect of berberine on TDP-43 pathogenesis
First, we were interested in investigating the effect of the
autophagy activator berberine on TDP-43 insoluble de-
position formation. To observe whether berberine can
prevent or dissolve TDP-43 aggregates, we overexpressed
GFP-tagged aggregation-prone C-terminal TDP-43 frag-
ments, GFP-TDP-25 [33, 34], and treated cells with differ-
ent dose of berberine before or after the initiation of
TDP-43 aggregates formation. Cells transfected with trun-
cated C-terminal TDP-43 fragments (TDP-25) started to
form insoluble cytosolic aggregates after 6 h transfection.
Accumulation of truncated TDP-43(+) UBIs aggregates in
cytosol in FTLD and ALS brains were identified as RIPA-
insoluble species and most of the aggregates are dissolved
in urea-soluble fractions in Western blot assay. To evalu-
ate the neuroprotective effect of berberine on preventing
insoluble TDP-43 formation, after 6 h transfection, the
GFP-TDP-25-transfected cells were treated with various
dose of berberine for another 24 h, and then the insoluble
TDP-43 were extracted with RIPA and urea buffer to
dissect the soluble and insoluble TDP-43 fractions and an-
alyzed by Western blotting (sequential extraction method,
please see Materials and Methods). Comparing to control
group, the insoluble fraction of TDP-43 (urea fraction)
was significantly lower in cells treated with berberine after
6 h transfection in a dose-dependent manner (Fig. 1a),
suggesting that berberine can provide neuroprotective ef-
fect to prevent insoluble TDP-43 accumulation. To further
validate the effect of berberine on inhibiting the formation
of pathological TDP-43 inclusion, the percentage of TDP-
43 aggregates in cells treated with berberine after 6 h
transfection were measured and quantified by immuno-
fluorescent assay. Comparing to control group, the aggre-
gation percentage of TDP-43 was significantly lower in
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cells treated with berberine after 6 h transfection in a
dose-dependent manner, especially in cells treated with 20
and 30 ug/ml of berberine (left panal in Fig. 2a and b),
suggesting that berberine not only decreased the depos-
ition of insoluble TDP-43 species, but also prevented the
TDP-43 aggregate formation.
To further monitor the potential therapeutic role of
berberine on dissolving the insoluble aggregated TDP-
43, we treated cells with berberine in GFP-TDP-25-
transfected N2a cells after TDP-43 aggregates formation.
After 24 h transfection, the GFP-TDP-25-transfected
cells were treated with different doses of berberine for
another 24 h and the insoluble TDP-43 fractions were
extracted by sequential extraction method and analyzed
by Western blotting. Comparing to control group, the
insoluble fraction of TDP-43 (urea fraction) showed a
dose-dependent decrease in cells treated with berberine
after 24 h transfection, (Fig. 1b), suggesting that berber-
ine can also reverse the insoluble TDP-43 accumulation.
To further validate the therapeutic effect of berberine on
TDP-43 aggregates formation, the percentage of TDP-43
aggregates were measured and quantified by immuno-
fluorescent assay in cells treated with berberine for 24 h
after 24 h post transfection. Comparing to control
group, the aggregation percentage of TDP-43 was sig-
nificantly lower in cells treated with berberine, especially
in cells treated with 20 and 30 ug/ml of berberine (right
panal in Fig. 2a and b). These results demonstrated that
berberine can both prevent and ameliorate the patho-
logical TDP-43 formation.
The mTOR-signaling pathway is involved in berberine-
mediated autophagy activation and TDP-43 aggregates
elimination
It has been demonstrated that berberine is a potent
autophagy activator through inhibiting mTOR signaling
pathways [24, 25]. Autophagy is the major catabolic
process to remove bulk cytoplasmic contents, abnormal
protein aggregates, and excess or damaged organelles.
The effect of berberine on reducing TDP-43 aggregates
led us to hypothesize that berberine affected the aggre-
gated TDP-43 processing through mTOR inhibition and
autophagy activation. To investigate whether mTOR-
regulated autophagy process is involved in berberine-
mediated clearance of pathogenic TDP-43, we examined
the levels of autophagic and mTOR activity markers,
LC3-II protein, by Western blotting. Reversion of LC3-I
into LC3-II is an indicator as the formation of autopha-
gosome in autophagy system [35]. After 6 h post trans-
fection, different dose of berberine were added into
GFP-TDP-25-transfected N2a cells for another 24 h. The
ratio of LC3-I/LC3-II were analyzed by Western blotting
and compared by densitometry. A lower ratio of LC3-I/
LC3-II indicates more conversion of LC3-I to LC3-II
during synthesis of the autophagosome and activation of
autophagy [35]. In GFP-TDP-25-transfected cells treated
with different dose of berberine, the insoluble TDP-43
species and protein ratio of LC3-I/LC3-II in berberine-
treated cells were both decreased in a dose-dependent
manners, comparing to that of control group (Fig 3a),
suggesting that berberine-mediated autophagosome
Fig. 1 The effect of berberine on insoluble TDP-43 accumulation. a and b After 6 h (a) and 24 h (b) transfection, N2a cells were transfected with
GFP-tagged aggregation-prone TDP-43 fragments (GFP-TDP-25) and treated with different dose of berberine for another 24 h. The soluble/insoluble
TDP-43 were extracted by RIPA/urea fractionation and analyzed by Western blotting with anti-GFP antibody
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formation and autophagy activation is involved in dimin-
ishing insoluble TDP-43 formation. It has been demon-
strated that activation of mTOR by phosphorylation
would further phosphorylate and activate p70S6K [36, 37].
Accordingly, we further detected the phosphorylation
level of both mTOR and p70S6K in berberine-treated
cells. After 6 h or 24 h post transfection, different dose of
berberine were added into GFP-TDP-25-transfected N2a
cells for another 24 h. Either in 6 h or 24 h post
transfected-cells, compared with control group, both of
the phosphorylated mTOR and p70S6K in cells treated
with berberine is significantly decreased in which their
protein levels were unchanged (Fig. 3b). Moreover,
consistent with the observation in Fig. 3a, we found
that the autophagosome marker LC3-II represented in
autolysosomes structure was significantly enhanced in
berberine-treated cells with higher dose compared
with control group (Fig. 4a and b). The above results
demonstrated that treatment of berberine would in-
hibit the mTOR signaling cascades and activate the
autophagy pathway to decrease the pathological TDP-
43 formation.
Inhibition of autophagy reverses the effect of berberine
on TDP-43 pathogenesis
To further confirm that the effect of berberine on de-
creasing TDP-43 aggregates is mediated by autophagy
activation, we inhibited autophagy by specific autopha-
gosome inhibitor, 3-MA (3-Methyladenine). 3-MA in-
hibits autophagy by blocking autophagosome formation
via inhibiting the mTOR key regulator, class III Phos-
phatidylinositol 3-kinases (PI-3 K), and is broadly used
to study autophagy-related mechanism under various
kinds of cellular condition [38]. We examined the TDP-
43 aggregates by immunofluorescent and Western blot
assays in GFP-TDP-25-transfected N2a cells treated with
berberine only or combined with 3-MA. The therapeutic
effect between 20 and 30 ug/ml of berberine in TDP-43-
aggregated cells were comparable (Fig. 1 and 2), yet cells
treated with 30 ug/ml of berberine showed minor
(See figure on previous page.)
Fig. 2 The effect of berberine on TDP-43 aggregates formation. a GFP-tagged aggregation-prone TDP-43 fragments (GFP-TDP-25) were transfected in
N2a cells. After 6 h or 24 h transfection, N2a cells were treated with different dose of berberine for another 24 h. GFP-TDP-25-transfected N2a cells were
then stained with anti-GFP antibody (green) in immunofluorescence assay. The nuclei were stained with DAPI (blue). b The histogram showing
the percentage of cells with GFP-TDP-43 aggregates. Data are presented as mean ± s.e.m. of three independent experiments *p < 0.05; **p < 0.01
(Student’s t-test compared with the control)
Fig. 3 The mTOR/p70S6K-signaling pathway is involved in berberine-mediated autophagy activation and TDP-43 aggregates diminishing. a and b N2a
cells were transfected with GFP-TDP-25 for 6 h or 24 h and then treated with berberine for another 24 h. Cell lysates were analyzed by Western
blotting with anti-GFP and anti-LC3, anti-p-mTOR, anti-mTOR, anti-p-p70S6 and anti-p70S6 antibodies. Data are presented as mean ± s.e.m.
of three independent experiments *p < 0.05; **p < 0.01; ***P < 0.005 (Student’s t-test compared with the control)
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cytotoxicity with relatively lower total cell numbers
(Fig. 2). Accordingly, 20 μg/ml berberine was used to
study the inhibition effect of 3-MA on berberine-
mediated decrease of TDP-43 aggregates. After 24 h post
transfection, GFP-TDP-25-transfected N2a cells were
added with 20 μg/ml berberine or 10 μM 3-MA for an-
other 24 h, and the TDP-43 aggregates were identified
under microscopy. In berberine-treated cells, GFP-TDP-
25 was obscure yet the autophagosome marker LC3-II
were significantly increased (Fig. 5a). However, in ber-
berine and 3-MA co-treated cells, the GFP-TDP-25 was
prominently enhanced but the signal of LC3-II was obvi-
ously reduced (Fig. 5b and d). Moreover, 3-MA also
reversed the effect of berberine on reducing the accumu-
lation of insoluble fraction of TDP-43 (urea fraction) in
Western blot assay (Fig. 5c). And the levels of insoluble
TDP-43 protein in berberine-treated cells was even
lower than that of cells in 0.5 μM rapamycine-treated
cells (Fig. 5c), suggesting that the effect of berberine is
better than rapamycin on diminishing insoluble TDP-43
accumulation. These results give us the notion that
inhibition of autophagy by 3-MA reverses the effect
of berberine on TDP-43 pathogenesis, and activation
of mTOR-regulated autophagy plays an important role
in berberine-mediated therapeutic effect on TDP-43
proteinopathies (Fig. 6).
Discussion
Most of the short-lived proteins are degraded by UPS
through the 26S proteasome [39], whereas the autophagy-
lysosomal pathway primarily catabolizes unnecessary or-
ganelles, long-lived proteins, and misfolded/aggregated
proteins [12]. To date, several studies have reported that
full-length TDP-43 protein and its truncated 25 kDa
and 35 kDa fragments are degraded through both the
ubiquitin-proteasome [13–15] and autophagy-lysosome
metabolism pathways [16–18]. TDP-43 is not only a sub-
strate for autophagy, but also as a maintenance factor of
the autophagy system by stabilizing the mRNA of
autophagy-related genes, ATG7 [40]. Autophagy is nega-
tively regulated by mTOR [11]. Induction of autophagy
would accelerate the removal of aggregation-prone pro-
teins and provides a neuroprotective effect in several neu-
rodegenerative disease models, including Huntington
disease [41], Alzheimer’s disease [42], Parkinson disease
[43]. The autophagy activator, rapamycin, which is an
antifungal and immunosuppressant compound that
targeting in inhibition of the mTOR signal, has been
identified its potential therapeutic effect on numerous
neurodegenerative diseases including TDP-43-related
pathogenesis [20–22]. However, the cytotoxicity of
rapamycin leading to the pathological failures have
also been reported in Alzheimer’s disease [44, 45] and
Fig. 4 The autophagy activation marker LC3-II is significantly increased in berberine-treated cells. a N2a cells were transfected with GFP-TDP-25.
After 6 h transfection, N2a cells were treated with different dose of berberine for another 24 h, and then stained with anti-LC3-II (red) in
immunofluorescence assay. The nuclei were stained with DAPI (blue). b Data are presented as mean ± s.e.m. of three independent experiments
***P < 0.005 (Student’s t-test compared with the control)
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ALS model study [23], which restricted its clinical
therapeutic application. Thus, an alternative new drug
targeting on activating the autophagy pathway with
less side effect would provide better therapeutic effect
on these neurodegenerative diseases including the
TDP-43 pathogenesis.
Recent studies have demonstrated that the traditional
herb medicine, berberine, is an isoquinoline alkaloid
found in a number of important medicinal plant species
and is a potent autophagy activator through inhibition of
the mTOR signal pathways [25, 30]. Berberine is a long-
term used herb medicine applied in broad clinical
Fig. 5 Inhibition of autophagy reverses the effect of berberine on TDP-43 aggregates elimination. a and b After 24 h transfection, N2a cells transfected
with GFP-TDP-25 were treated with 20 μg/ml berberine and autophagy inhibitor 10 μM 3-MA for another 24 h, and stained with anti-GFP (green) and
anti-LC3-II (red). c and d The soluble/insoluble TDP-43 were extracted by RIPA/urea fractionation and analyzed by Western blotting with anti-GFP and
anti-LC3 antibodies
Fig. 6 Schematic diagram of the mechanism of berberine on reversing the aggregated TDP-43 processing through mTOR inhibition and autophagy
activation in cells with TDP-43 pathogenesis
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diseases and is even used as dietary nutritional supple-
ment or orally-taken drug since its low side effect and
cellular toxicity. Several studies have reported that the
natural compound berberine, with either the extract or
pure berberine, is safely administered to humans, and is
used in various kinds of diseases, such as antibacterial,
anti-hypertensive, anti-inflammatory, anti-diabetic, anti-
hyperlipidemic and anti-cancer effects [46, 47]. Berberine
can be safely used to treat a number of diseases, and
even partly replace the commercial drugs, which could
lead to a reduction in toxicity and side effects [48]. Pre-
liminary results suggest the initiation of clinical trials in
patients with neuronal related diseases, such as depres-
sion, bipolar affective disorder, schizophrenia, or related
diseases in which cognitive capabilities are affected
[49, 50]. The high tolerance for orally-taken doses
(LD50 > 5 g/kg) and the freely blood–brain-barrier
permeability of berberine [26] make it an ideal drug
candidate for chronic neurological disorders. Recently,
several studies have found that berberine is a potential
neuroprotector for several neurodegenerative pathogen-
esis, including Parkinson’s disease, Huntington’s diseases
and Alzheimer’s disease (AD) through ameliorating the
β-amyloids deposition, or enhancing the degradation of
mutant huntingtin by autophagic pathway [27–31]. Here
we also demonstrated that berberine promotes the
metabolism rates and decrease the aggregates forma-
tion of truncated TDP-43 fragments through activat-
ing the autophagic function in cellular culture model,
implying its potential neuroprotective effects on neu-
rodegenerative diseases with TDP-43 proteinopathies.
Berberine also exhibits multifaceted pharmacological
effects on neuroprotection or againsting neurodegeneration
through shared signaling pathways. In both Alzheimer’s
and Parkinson’s patients, monoamine oxidase B (MAO-B)
activity is elevated and MAO-B-mediated dopamine me-
tabolism pathway leading to H2O2 generation would cause
oxidative stress and reactive oxygen species (ROS)-me-
diated damage [51]. Berberine-counteracted MAO-B
and ROS activity has positive effects on againsting pro-
apoptotic damage in numerous neurodegenerative
diseases [29, 52, 53]. Additionally, berberine also atten-
uates hydrogen peroxide-induced neurotoxicity through
up-regulation of nuclear factor erythroid 2 (Nrf2),
glycagon-like protein 1 (GLP-1), as well as phosphoryl-
ation of Protein kinase B (AKT) and cyclic adenosine
monophosphate response element- binding protein
(CREB) [54–58]. GLP-1 plays a role in preservation of
dopaminergic neurons and phosphorylated CREB is
essential for neurons to survive damage [59–62]. Fur-
thermore, AChE would induce neuronal apoptotic and
berberine-mediated inhibition of AChE has broadly
effect on a great number of neurodegenerative dis-
eases [63]. Berberine exhibits broad neuroprotective
properties through various known signaling pathways.
As for the adverse effects of berberine, limited evi-
dence has been reported. It has been reported that a
dose of 5–15 mg/kg berberine would decrease the
number of dopaminergic neurons in the substantia
nigra and the striatum, suggesting its toxic effect on
disturbing the motors and cognitive functions [64].
Furthermore, berberine would inhibit the dopamine
synthesis and enhance neurotoxicity of 6- hydroxydo-
pamine in cell culture system leading to neurotoxic at
the dose of 10–30 mM [65]. Recently, berberine was
found to cause mitochondria-dependent toxicity and
sensitize neurons to the glutamate excitotoxicity in
cultured primary neurons [66]. To better understand
the toxicity of the berberine, exploring the potential
side effects of berberine is indispensible.
Berberine has been identified as a potent autophagy
activator through inhibiting mTOR signaling pathways
[24, 25]. Autophagy is a catabolic process that results in
the autophagosomic-lysosomal degradation of bulk cyto-
plasmic contents, abnormal protein aggregates, and ex-
cess or damaged organelles. Autophagy is inhibited by
the mTOR signaling and generally activated by condi-
tions of nutrient deprivation, oxidation, infection and
tumor suppression [67]. Activation of mTOR by Akt or
MAPK signaling would further phosphorylate and acti-
vate its downstream serine/threonine kinase p70S6K,
and also suppress the initiation of a cascade of autoph-
agy related genes (Atg) expression and autophagy activa-
tion [36, 37]. Previous studies have demonstrated that
berberine possesses multiple activities in Alzheimer's
disease therapy, including antioxidant activity, AChE
and BChE inhibitory activity, MAO inhibitory activity,
and reducing Aβ level and lowering cholesterol [58].
Berberine can be administered orally and pass through
the blood–brain barrier [26, 68], suggesting its potential
effect for FTLD and ALS. Here we found that berberine
reverses the aggregated TDP-43 processing through in-
hibition of mTOR/p70S6K signal and autophagy activa-
tion in FTLD and ALS pathogenesis. In addition, the
ratios of LC3-I/LC3-II in berberine-treated N2a cells
were significantly decreased (Fig 3a), indicating that
berberine enhances autophagosome formation and fur-
ther triggers the following autolysosome activation.
When we inhibited autophagy by specific PI-3 K inhibitor,
3-MA, which specifically inhibits the formation of autop-
hagosome during autophagy process, a reverse effect of
berberine on autophagy activation and TDP-43 aggregates
elimination were observed (Fig. 5). These results further
confirming that activation of mTOR-regulated autophagy
plays an important role in berberine-mediated therapeutic
effect on TDP-43 proteinopathies (Fig. 6). We explored
the detailed molecular mechanism of berberine on TDP-
43 metabolism and insoluble TDP-43 deposition, and
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provided a better alternative therapeutic strategy for FTLD
and ALS diseases.
Conclusions
We supported an important notion that the traditional
herb berberine is a potential alternative therapy for TDP-
43-related neuropathology, Here we demonstrated that ber-
berine is able to reverse the processing of insoluble TDP-43
aggregates formation through deregulation of mTOR/
p70S6K signal and activation of autophagic degradation
pathway. mTOR-autophagy signals plays an important role
in berberine-mediated autophagic clearance of TDP-43 ag-
gregates. Exploring the detailed mechanism of berberine
on TDP-43 proteinopathy provides a better understanding
for the therapeutic development in FTLD and ALS.
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